Profile data is unavailable for this security.
About the company
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.
- Revenue in CNY (TTM)29.19bn
- Net income in CNY6.84bn
- Incorporated1997
- Employees20.24k
- LocationJiangsu Hengrui Pharmaceuticals Co LtdNo.7 Kunlunshan RoadLianyungang Eco & Tech Development ZoneLIANYUNGANG 222000ChinaCHN
- Phone+86 2 161053323
- Fax+86 2 161063801
- Websitehttps://www.hengrui.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UCB SA | 51.34bn | 8.89bn | 282.43bn | 9.38k | 31.74 | 3.30 | 20.51 | 5.50 | 5.48 | 5.48 | 31.62 | 52.77 | 0.3741 | 1.50 | 4.48 | 656,003.40 | 6.48 | 4.98 | 7.97 | 6.20 | 71.52 | 71.71 | 17.31 | 13.00 | 0.9858 | 8.91 | 0.2319 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| Alnylam Pharmaceuticals, Inc. | 16.85bn | -1.94bn | 303.88bn | 2.23k | -- | 366.53 | -- | 18.03 | -2.09 | -2.09 | 18.27 | 0.8858 | 0.5842 | 4.12 | 9.70 | 1,052,959.00 | -6.71 | -20.07 | -8.96 | -25.51 | 86.01 | 84.18 | -11.49 | -55.19 | 2.98 | -0.4627 | 0.8988 | -- | 22.97 | 59.21 | 36.82 | -- | -24.55 | -- |
| Haleon PLC | 108.11bn | 13.88bn | 310.26bn | 24.00k | 22.84 | 2.01 | -- | 2.87 | 0.1571 | 0.1571 | 1.22 | 1.79 | 0.3286 | 3.39 | 5.49 | 468,041.70 | 4.31 | 3.67 | 5.11 | 4.23 | 60.75 | 62.28 | 13.13 | 11.97 | 0.7791 | 8.48 | 0.3843 | 218.65 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| Daiichi Sankyo Co Ltd | 90.97bn | 14.26bn | 327.81bn | 19.77k | 23.02 | 4.13 | 18.66 | 3.60 | 155.87 | 155.87 | 994.10 | 869.69 | 0.5454 | 0.8726 | 4.24 | 95,434,150.00 | 8.55 | 5.72 | 10.87 | 7.11 | 77.96 | 72.15 | 15.68 | 11.03 | 1.85 | -- | 0.0876 | 49.57 | 17.77 | 13.95 | 44.47 | 17.77 | 29.01 | 20.79 |
| Takeda Pharmaceutical Co Ltd | 220.96bn | 5.21bn | 338.53bn | 47.46k | 66.01 | 1.00 | 8.07 | 1.53 | 66.83 | 66.83 | 2,880.43 | 4,407.01 | 0.3121 | 1.30 | 7.25 | 96,545,170.00 | 0.7367 | 1.71 | 0.8815 | 2.04 | 65.51 | 67.66 | 2.36 | 5.99 | 0.5202 | 2.52 | 0.3943 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| Sun Pharmaceutical Industries Ltd | 43.81bn | 9.11bn | 340.53bn | 43.00k | 37.39 | 5.66 | 30.15 | 7.77 | 45.55 | 45.55 | 219.13 | 300.99 | 0.5921 | 1.07 | 4.33 | 12,227,540.00 | 12.36 | 9.09 | 15.83 | 12.38 | 79.56 | 73.38 | 20.88 | 16.07 | 2.33 | 272.98 | 0.0316 | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 29.19bn | 6.84bn | 368.26bn | 20.24k | 53.46 | 7.84 | -- | 12.61 | 1.08 | 1.08 | 4.61 | 7.37 | 0.598 | 1.81 | 6.05 | 1,442,469.00 | 14.02 | 12.67 | 15.31 | 14.00 | 85.50 | 85.64 | 23.45 | 20.06 | 9.98 | -- | 0.0023 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| Merck KGaA | 177.88bn | 23.51bn | 404.73bn | 62.60k | 17.20 | 1.63 | 10.20 | 2.28 | 6.48 | 6.48 | 49.08 | 68.59 | 0.4312 | 1.88 | 4.89 | 340,745.30 | 5.71 | 6.04 | 7.12 | 7.70 | 59.21 | 61.15 | 13.24 | 13.80 | 0.8313 | 32.43 | 0.2252 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
| Regeneron Pharmaceuticals Inc | 101.11bn | 32.30bn | 426.23bn | 15.11k | 14.00 | 2.03 | 11.89 | 4.22 | 39.30 | 39.30 | 123.45 | 271.60 | 0.3917 | 0.6347 | 2.61 | 932,457.30 | 12.51 | 18.52 | 13.89 | 21.13 | 86.69 | 87.22 | 31.94 | 37.92 | 4.03 | -- | 0.0843 | -- | 8.27 | 12.55 | 11.61 | 15.84 | 15.46 | -- |
| Zoetis Inc | 66.65bn | 18.07bn | 479.44bn | 13.80k | 26.94 | 14.38 | 22.13 | 7.19 | 5.57 | 5.57 | 20.54 | 10.44 | 0.6529 | 1.07 | 7.00 | 672,898.60 | 17.77 | 15.25 | 21.83 | 18.31 | 70.98 | 70.18 | 27.22 | 26.32 | 1.04 | 21.14 | 0.5856 | 28.93 | 8.33 | 8.14 | 6.06 | 10.63 | 7.32 | 21.37 |
Data as of Jul 18 2025. Currency figures normalised to Jiangsu Hengrui Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
12.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 31 Dec 2024 | 207.13m | 3.25% |
| China Asset Management Co., Ltd.as of 30 Apr 2025 | 151.86m | 2.39% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 31 Dec 2024 | 91.87m | 1.44% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2024 | 88.93m | 1.40% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2024 | 75.34m | 1.18% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2024 | 56.12m | 0.88% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2024 | 45.25m | 0.71% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2024 | 33.57m | 0.53% |
| GF Fund Management Co., Ltd.as of 31 Dec 2024 | 29.03m | 0.46% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2024 | 25.02m | 0.39% |
More ▼
Data from 31 Dec 2024 - 30 Apr 2025Source: FactSet Research Systems Inc.
